BioXell Enters License Agreement with Merck & Co., Inc. for TREM-1 Product Candidate and TREM Platform
Under the terms of the agreement, BioXell will receive an up-front payment and, in addition, BioXell could receive as much as $150 million in milestone payments, including $55.5 million for the successful development of the first product for the first indication, and additional milestone payments for further development of the first candidate and follow-on product candidates in subsequent indications. BioXell also has rights to royalties on future product sales, upon completion of all required clinical trials and product approvals. Merck will be responsible for clinical development and commercialization of products worldwide.
TREM, an acronym for Triggering Receptors Expressed on Myeloid Cells, is a novel class of receptors that have been implicated in many diseases. TREM-1 is believed to play a key role in sepsis. Other aspects of the TREM platform show promise in several other indications.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.